Moderna COVID-19 vaccine

Free Digital COVID-19 Vaccine Card Service Now Available for Talbot County Residents

Retrieved on: 
Tuesday, July 20, 2021
COVID-19 vaccines, Clinical trials, RNA vaccines, Medical specialties, Medicine, COVID-19, COVID-19 vaccine card, Pfizer–BioNTech COVID-19 vaccine, Health, Vaccine, Moderna COVID-19 vaccine

EASTON, Md., July 20, 2021 /PRNewswire/ -- TalbotCounty Health Department and PinPoint US, LLC are partnering to offer free digital COVID-19 vaccine cards forTalbotCounty residents.

Key Points: 
  • EASTON, Md., July 20, 2021 /PRNewswire/ -- TalbotCounty Health Department and PinPoint US, LLC are partnering to offer free digital COVID-19 vaccine cards forTalbotCounty residents.
  • TheVaccineCheckservice will generate a personalized digital version of a CDC vaccine card after verifying COVID-19 vaccine history through Maryland's statewide immunization registry.
  • Residents can also use the service to upload images of their paper CDC vaccine card for safe digital record-keeping accessible through their smartphone or computer.
  • Many residents live and work in different jurisdictions, so we are pleased to offer this vaccine verification service across state and county lines," says Chris Nickerson, VaccineCheck Managing Partner.

Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022

Retrieved on: 
Tuesday, July 20, 2021
Health, Infectious diseases, Genetics, Other Health, Pharmaceutical, Biotechnology, COVID-19 vaccines, Clinical trials, Medicine, Medical research, Health sciences, RNA vaccines, Health, BioNTech, Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine, COVID-19 vaccine, Moderna

This new supply agreement is in addition to the prior agreement for 50 million doses in 2021 resulting in a total of 100 million doses for Japan.

Key Points: 
  • This new supply agreement is in addition to the prior agreement for 50 million doses in 2021 resulting in a total of 100 million doses for Japan.
  • Moderna is responsible for the manufacture and supply of Modernas vaccine candidate, and Takeda, with the support of the MHLW and Moderna, is responsible for all import, local regulatory, development and distribution activities in Japan for these additional 50 million doses beginning in 2022.
  • We thank the MHLW and Takeda for their support and for partnering with us to bring our mRNA COVID-19 vaccine to Japan, said Stphane Bancel, Modernas Chief Executive Officer.
  • We remain committed to making our vaccine available around the world as we seek to address the pandemic.

Moderna to Report Second Quarter Financial Results on Thursday, August 5, 2021

Retrieved on: 
Thursday, July 15, 2021
Research, Infectious diseases, Clinical trials, Other Health, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Conference call, Moderna COVID-19 vaccine

ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results, and provide a corporate update.

Key Points: 
  • ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results, and provide a corporate update.
  • To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 5749439.
  • A webcast of the call will also be available under Events and Presentations in the Investors section of the Moderna website at investors.modernatx.com.
  • Moderna has been named a top biopharmaceutical employer by Science for the past six years.

Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine

Retrieved on: 
Monday, July 12, 2021
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious diseases, Clinical trials, COVID-19, COVID-19 vaccines, Clinical trials, Medicine, Vaccines, Medical research, RNA vaccines, BioNTech, Moderna COVID-19 vaccine, Pfizer–BioNTech COVID-19 vaccine, COVID-19 vaccine, Moderna, the COVID-19 Vaccine Moderna, Moderna, THE COVID-19 VACCINE MODERNA, MODERNA

We appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates, said Stphane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • We appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates, said Stphane Bancel, Chief Executive Officer of Moderna.
  • We are committed to making our vaccine available around the world as we seek to address the pandemic with our COVID-19 vaccine.
  • The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein.
  • Moderna has filed for emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adolescents with global health agencies.

Studio Moderna Group Appoints New Chief Digital Officer to Accelerate the Company's Digital Transformation

Retrieved on: 
Monday, July 12, 2021
Online Retail, Advertising, Retail, Communications, Technology, Home Goods, Internet, Articles, E-commerce, Marketing, Omnichannel, Digital transformation, Studio Moderna, Moderna COVID-19 vaccine, Moderna

Studio Moderna Group, the leader in home and living omnichannel and eCommerce in Central and Eastern Europe, announced today that Vincent Lootens has joined the company as Chief Digital Officer.

Key Points: 
  • Studio Moderna Group, the leader in home and living omnichannel and eCommerce in Central and Eastern Europe, announced today that Vincent Lootens has joined the company as Chief Digital Officer.
  • Vincent Lootens will be reporting directly to CEO Jan Heere and will be responsible for companys digital transformation strategy and omnichannel acceleration.
  • I am thrilled to have Vincent join our executive management team and bring weight of experience in e-commerce and digital as we work to enhance digital focus and accelerate digital transformation of Studio Moderna Group.
  • "I am excited to join Studio Moderna Group as Chief Digital Officer to carry out the transformation of the company into a strong seamless omnichannel player across its different markets.

Moderna Vice President of US Manufacturing to Deliver Keynote Address at the 2021 ISPE Facilities of the Future Conference

Retrieved on: 
Thursday, July 8, 2021
Health sciences, Health care, Health, Pharmaceuticals policy, GxP, Medical research, Alexion Pharmaceuticals, Pharmaceutical industry in India, Pharmaceutical industry in China, Moderna COVID-19 vaccine, Moderna, Quality assurance

Nickerson joined Moderna in May 2016 as Head of Quality accountable for all aspects of GxP Quality.

Key Points: 
  • Nickerson joined Moderna in May 2016 as Head of Quality accountable for all aspects of GxP Quality.
  • Before Moderna, he was with Alexion Pharmaceuticals serving as Vice President of Quality Assurance and Quality Control.
  • The opening keynote session COVID's Impact on Pharma Facilities of the Future will take a high-level look ahead at global pharmaceutical manufacturing and related regulatory systems.
  • Nickerson will discuss the impact of COVID on the industry and the applications of future manufacturing operations.

Medolife Rx Clinical Observations Demonstrates Effectiveness of Escozine in Complementary Use with COVID-19 Vaccines

Retrieved on: 
Thursday, July 8, 2021
Medicine, Health, Virology, Clinical trials, Clinical pharmacology, Vaccination, Vaccine, Moderna COVID-19 vaccine, Adverse effect

Physicians observed that patients who originally had strong adverse reactions to COVID-19 vaccines and who were given Escozine, experienced significantly lessened side effects.

Key Points: 
  • Physicians observed that patients who originally had strong adverse reactions to COVID-19 vaccines and who were given Escozine, experienced significantly lessened side effects.
  • Escozine, which is comprised of scorpion peptides that have been polarized by the Companys proprietary process, is Medolifes lead drug candidate.
  • Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products.
  • Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications.

Moderna Announces Recipharm Site in France Manufacturing COVID-19 Vaccine Moderna Following Approval by European Medicines Agency

Retrieved on: 
Thursday, July 1, 2021
Biotechnology, Pharmaceutical, Other Manufacturing, Medical Supplies, General Health, Health, Infectious diseases, Manufacturing, COVID-19 vaccines, Clinical trials, RNA vaccines, Medicine, Health, Medical research, Moderna COVID-19 vaccine, RNA, COVID-19 vaccine, Recipharm, RNA vaccine, Vaccine, the COVID-19 Vaccine Moderna, Moderna, THE COVID-19 VACCINE MODERNA, MODERNA

France is at the heart of European innovation in healthcare and will play an important role in Modernas strategic growth plan.

Key Points: 
  • France is at the heart of European innovation in healthcare and will play an important role in Modernas strategic growth plan.
  • Our collaboration with Moderna has created a strong foundation for vaccine production in France, leveraging our manufacturing excellence to ensure the timely delivery of the Moderna COVID-19 vaccine to Europe, said Marc Funk, CEO of Recipharm.
  • Modernas partnership with Recipharm is reflective of the Companys commitment to expanding its global manufacturing capacity.
  • The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein.

Melbourne, Australia Develops Next-Generation mRNA COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, July 1, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Nucleic acids, COVID-19 vaccines, RNA vaccines, Clinical trials, RNA, Medical research, RNA vaccine, Moderna COVID-19 vaccine, Pfizer–BioNTech COVID-19 vaccine, COVID-19 vaccine, Messenger RNA, Vaccine

mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the States mRNA manufacturing and research capability announced that a locally-developed COVID vaccine candidate will enter Phase 1 clinical trials in October, 2021.

Key Points: 
  • mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the States mRNA manufacturing and research capability announced that a locally-developed COVID vaccine candidate will enter Phase 1 clinical trials in October, 2021.
  • mRNA Victoria will fund the Monash Institute of Pharmaceutical Sciences (MIPS) to manufacture doses of the mRNA COVID-19 vaccine for trials, establishing Australias first manufacturing capability of mRNA vaccines.
  • While mRNA Victoria is charged with building Victorias mRNA manufacturing capability to fast-track Australias future supply of coronavirus vaccines, there are wider-ranging implications to its mission.
  • Australias first locally-developed mRNA COVID-19 vaccine candidate is a collaboration between MIPS and the Peter Doherty Institute for Infection and Immunity (Doherty Institute), reflecting the strong mRNA research sector in Victoria and leading the national charge to develop mRNA manufacturing capability.

Advisory - Health Canada updates Pfizer-BioNTech and Moderna COVID-19 vaccine labels to include information on myocarditis and pericarditis

Retrieved on: 
Wednesday, June 30, 2021
Medical specialties, Medicine, Health, BioNTech, COVID-19 vaccines, Clinical trials, RNA vaccines, Medical research, Pfizer–BioNTech COVID-19 vaccine, Myocarditis, Vaccine, Moderna COVID-19 vaccine

Issue:Health Canada has updated the product monographs (labels) for the Pfizer-BioNTech and Moderna COVID-19 vaccines to describe very rare reports of myocarditis and pericarditis following vaccination.

Key Points: 
  • Issue:Health Canada has updated the product monographs (labels) for the Pfizer-BioNTech and Moderna COVID-19 vaccines to describe very rare reports of myocarditis and pericarditis following vaccination.
  • Health Canada has updated the product monographs (labels) for the Pfizer-BioNTech and Moderna COVID-19 vaccines to describe very rare reports of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) following vaccination.
  • Cases of myocarditis and/or pericarditis following immunization with COVID-19 vaccines have been reported in a small number of people in Canada and internationally.
  • For further information on COVID-19 vaccines in Canada, please visit Health Canada's COVID-19 vaccines and treatments portal .